Active — Not RecruitingPhase 2

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

United States30 participantsStarted 2017-02-27

Plain-language summary

The purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Total bilirubin ≤ 2.0 mg/dL, unless due to Gilbert's disease
✓. Serum creatinine ≤ 2.0 mg/dL.
✓. ALT and AST ≤ 3 x upper limit of normal (unless the transaminitis is considered to be related to MF, in which case ≤5 x ULN is allowed

What they're measuring

best objective response rate (ORR)

Timeframe: 1 year

Trial details

NCT IDNCT03069326

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02

View on ClinicalTrials.gov More Myelofibrosis trials